The estimated Net Worth of Sath Shukla is at least $1.71 Milión dollars as of 27 August 2024. Sath Shukla owns over 2,757 units of Spero Therapeutics Inc stock worth over $1,528,684 and over the last 5 years Sath sold SPRO stock worth over $184,641.
Sath has made over 6 trades of the Spero Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Sath sold 2,757 units of SPRO stock worth $3,722 on 27 August 2024.
The largest trade Sath's ever made was selling 75,994 units of Spero Therapeutics Inc stock on 1 February 2024 worth over $107,911. On average, Sath trades about 11,061 units every 61 days since 2019. As of 27 August 2024 Sath still owns at least 1,140,809 units of Spero Therapeutics Inc stock.
You can see the complete history of Sath Shukla stock trades at the bottom of the page.
Sath's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela a Capital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.
spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
Spero Therapeutics Inc executives and other stock owners filed with the SEC include: